A Randomized Clinical Trial of Repetitive Transcranial Magnetic Stimulation (rTMS) Treatment for Obsessive-Compulsive Disorder
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Obsessive-Compulsive Disorder
- Sponsor
- Shanghai Mental Health Center
- Enrollment
- 53
- Locations
- 1
- Primary Endpoint
- Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale
- Status
- Completed
- Last Updated
- 11 months ago
Overview
Brief Summary
This study will evaluate the possible therapeutic effects of repetitive transcranial magnetic stimulation(rTMS) in obsessive-compulsive disorder (OCD) in OCD patients who have not fully responded to pharmacotherapy, and the underlying neural mechanism by EEG.
Detailed Description
The purpose of study is to examine the efficacy of rTMS over different brain areas, including the bilateral supplement motor Area (SMA), the right dorsal lateral prefrontal cortex (DLPFC) and SMA+DLPFC in the treatment of OCD. 120 OCD patients will be randomized into four groups. Continuous theta burst stimulation (cTBS) stimulation will be performed once a day, five times a week, for four weeks. The investigators will assess improvement after four weeks of cTBS. Though the study, Yale-Brown Obsessive Compulsive Scale（Y-BOCS）, the Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS), the Barratt Impulsiveness Scale-11 (BIS-11), the Beck Depression Inventory(BDI), the Beck Anxiety Inventory (BAI), Perceived Stress Scale(PSS), Pittsburgh sleep quality index(PSQI), the Obsessive-Compulsive Inventory-Revised(OCI-R) and side effects will be obtained by a trained investigator. The patients will also receive magnetic resonance imaging scan and electroencephalography (EEG).
Investigators
Zhen Wang
vice-president
Shanghai Mental Health Center
Eligibility Criteria
Inclusion Criteria
- •age\>18 years old;
- •DSM-5 criteria for OCD;
- •Y-BOCS total score \> or = 16, despite treatment with an adequate trial of a serotonin reuptake inhibitor (SRI) and currently using adequate, stable dose of SRI at least 4 weeks. An adequate SRI trial is defined as treatment for at least 12 weeks on the SRI, that meets or exceeds the recommended dosage level for OCD;
- •\>or＝9 yrs education
Exclusion Criteria
- •any additional current psychiatric comorbidity, except for obsessive-compulsive personality disorder
- •serious suicide risk;
- •the inability to receive rTMS because of metallic implants, or history of seizures，or history of head injury, or history of neurosurgery;
- •any major medical disease;
- •pregnancy or nursing of an infant;
- •participation in current clinical study;
- •current use of any investigational drug;
- •TMS/DBS treatment at any point in their lifetime;
- •history of long-time use of benzodiazepines
Outcomes
Primary Outcomes
Symptom improvement assessed by the Yale-Brown Obsessive Compulsive Scale
Time Frame: Up to 6 months
The responder on Y-BOCS is defined as a Y-BOCS decrease at least 25% from the baseline at post-treatment
Secondary Outcomes
- The Barratt Impulsiveness Scale-11 (BIS-11)(Up to 6 months)
- The Dimensional Yale-Brown Obsessive-Compulsive Scale (DY-BOCS)(Up to 6 months)
- The Beck Anxiety Inventory (BAI)(Up to 6 months)
- The Beck Depression Inventory(BDI)(Up to 6 months)
- side effects(Up to 6 months)
- State-trait Anxiety Inventory(STAI)(Up to 6 months)
- Perceived Stress Scale(PSS)(Up to 6 months)
- Pittsburgh sleep quality index(PSQI)(Up to 6 months)
- The Obsessive-Compulsive Inventory-Revised(OCI-R)(Up to 6 months)